The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older
Open accessAbstract
Importance: Data are limited regarding statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults 75 years and older. Objective: To evaluate the role of statin use for mortality and primary prevention of ASCVD in veterans 75 years and older. Design, Setting, and Participants: Retrospective cohort study that used Veterans Health Administration (VHA) data on adults 75 years and older, free of ASCVD, and with a clinical visit in 2002-2012. Follow-up continued through December 31, 2016. All data were linked to Medicare and Medicaid claims and pharmaceutical data. A new-user design was used, excluding those with any prior statin use. Cox proportional hazards models were fit to evaluate the association of statin use with outcomes. Analyses were conducted using propensity score overlap weighting to balance baseline characteristics. Exposures: Any new statin prescription. Main Outcomes and Measures: The primary outcomes were all-cause and cardiovascular mortality. Secondary outcomes included a composite of ASCVD events (myocardial infarction, ischemic stroke, and revascularization with coronary artery bypass graft surgery or percutaneous coronary intervention). Results: Of 326 981 eligible veterans (mean [SD] age, 81.1 [4.1] years; 97% men; 91% white), 57 178 (17.5%) newly initiated statins during the study period. During a mean follow-up of 6.8 (SD, 3.9) years, a total 206 902 deaths occurred including 53 296 cardiovascular deaths, with 78.7 and 98.2 total deaths/1000 person-years among statin users and nonusers, respectively (weighted incidence rate difference [IRD]/1000 person-years, -19.5 [95% CI, -20.4 to -18.5]). There were 22.6 and 25.7 cardiovascular deaths per 1000 person-years among statin users and nonusers, respectively (weighted IRD/1000 person-years, -3.1 [95 CI, -3.6 to -2.6]). For the composite ASCVD outcome there were 123 379 events, with 66.3 and 70.4 events/1000 person-years among statin users and nonusers, respectively (weighted IRD/1000 person-years, -4.1 [95% CI, -5.1 to -3.0]). After propensity score overlap weighting was applied, the hazard ratio was 0.75 (95% CI, 0.74-0.76) for all-cause mortality, 0.80 (95% CI, 0.78-0.81) for cardiovascular mortality, and 0.92 (95% CI, 0.91-0.94) for a composite of ASCVD events when comparing statin users with nonusers. Conclusions and Relevance: Among US veterans 75 years and older and free of ASCVD at baseline, new statin use was significantly associated with a lower risk of all-cause and cardiovascular mortality. Further research, including from randomized clinical trials, is needed to more definitively determine the role of statin therapy in older adults for primary prevention of ASCVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationArnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Variable Selection for Propensity Score Models
Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj149 · Cited by 2,336
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.182615 · Cited by 914
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Comparison of Propensity Score Methods and Covariate Adjustment
Elze, M. C., Gregson, J., Baber, U., Williamson, E., Sartori, S., Mehran, R., Nichols, M., Stone, G. W., & Pocock, S. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.060 · Cited by 713
Addressing extreme propensity scores via the overlap weights
Li, F., & Thomas, L. E. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwy201 · Cited by 694
The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs
Yazdanyar, A., & Newman, A. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.07.007 · Cited by 666
Kutner, J. S., Blatchford, P. J., Taylor, D. H., Ritchie, C. S., Bull, J. H., Fairclough, D. L., Hanson, L. C., LeBlanc, T. W., Samsa, G. P., Wolf, S., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0289 · Cited by 502
Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease
Savarese, G., Gotto, A. M., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.069 · Cited by 219
Ramos, R., Comas-Cufí, M., Martí-Lluch, R., Balló, E., Ponjoan, A., Alves-Cabratosa, L., Blanch, J., Marrugat, J., Elosua, R., Grau, M., et al. (2018) · BMJ · doi:10.1136/bmj.k3359 · Cited by 215
Han, B. H., Sutin, D., Williamson, J. D., Davis, B. R., Piller, L. B., Pervin, H., Pressel, S. L., Blaum, C. S., & for the ALLHAT Collaborative Research Group (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1442 · Cited by 177
Giral, P., Neumann, A., Weill, A., & Coste, J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz458 · Cited by 166
Health, R. (2015) · RAND Corporation eBooks · doi:10.7249/rr1165.1 · Cited by 159
Price, L. E., Shea, K., & Gephart, S. M. (2015) · Nursing Administration Quarterly · doi:10.1097/naq.0000000000000118 · Cited by 153
Primary Prevention With Statin Therapy in the Elderly
Ridker, P. M., Lonn, E., Paynter, N. P., Glynn, R. J., & Yusuf, S. (2017) · Circulation · doi:10.1161/circulationaha.117.028271 · Cited by 140
Teng, M., Lin, L., Zhao, Y. J., Khoo, A. L., Davis, B. R., Yong, Q. W., Yeo, T. C., & Lim, B. P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0290-9 · Cited by 108
Eibner, C., Krull, H., Brown, K. M., Cefalu, M., Mulcahy, A. W., Pollard, M., Shetty, K. D., Adamson, D. M., Amaral, E. F. L., Armour, P., et al. (2016) · Europe PMC (PubMed Central) · Cited by 106
Do Veterans Health Administration Enrollees Generalize to Other Populations?
Wong, E. S., Wang, V., Liu, C., Hebert, P. L., & Maciejewski, M. L. (2015) · Medical Care Research and Review · doi:10.1177/1077558715617382 · Cited by 99
Use of Propensity Score Technique to Account for Exposure-Related Covariates
Seeger, J. D., Kurth, T., & Walker, A. M. (2007) · Medical Care · doi:10.1097/mlr.0b013e318074ce79 · Cited by 89
Floyd, J. S., Blondon, M., Moore, K. P., Boyko, E. J., & Smith, N. L. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3921 · Cited by 81
Individualizing Prevention for Older Adults
Lee, S. J., & Kim, C. M. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15216 · Cited by 62
Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men
Orkaby, A. R., Gaziano, J. M., Djoussé, L., & Driver, J. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14993 · Cited by 58
Self-citationBezin, J., Moore, N. D., Mansiaux, Y., Steg, P. G., & Pariente, A. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.12.032 · Cited by 55
Hawley, C. E., Roefaro, J., Forman, D. E., & Orkaby, A. R. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00673-w · Cited by 55
Self-citationStatin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study
Kim, K., Lee, C. J., Shim, C. Y., Kim, J., Kim, B., Park, S., Chang, H., Hong, G., Ko, Y., Kang, S., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.026 · Cited by 45
Jun, J. E., Cho, I.-J., Han, K., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.030 · Cited by 38
Remembering Statins: Do Statins Have Adverse Cognitive Effects?
Bitzur, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3022 · Cited by 33
Huesch, M. D. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.7844 · Cited by 9
Association of statin therapy with incidence of Type 2 diabetes among US Veterans
Djoussé, L., Song, R. J., Cho, K., Gaziano, J. M., & GAGNON, D. R. (2019) · Journal of Clinical Cardiology and Cardiovascular Therapy · doi:10.31546/jcccvt.1002 · Cited by 8
Self-citation
Cited by
Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32332-1 · Cited by 318
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Self-citationRoadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
Metadata
- Authors
- Orkaby, A. R., Driver, J. A., Ho, Y.-L., Lu, B., Costa, L., Honerlaw, J., Galloway, A., Vassy, J. L., Forman, D. E., Gaziano, J. M., Gagnon, D. R., Wilson, P. W. F., Cho, K., & Djousse, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-07-07
- Volume
- 324
- Issue
- 1
- Pages
- 68
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3039401323
- Cited by
- 260
- References
- 35
- FWCI
- 36.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.